Ipragliflozin/sitagliptin - Astellas Pharma/MSD KKAlternative Names: Ipragliflozin L-proline/sitagliptin phosphate - Astellas Pharma/MSD KK; MK 0431J; Sitagliptin phosphate/ipragliflozin L-proline - Astellas Pharma/MSD KK; Sitagliptin/ipragliflozin - Astellas Pharma/MSD KK
Latest Information Update: 21 Mar 2017
At a glance
- Originator Astellas Pharma; MSD KK
- Class Antihyperglycaemics; Glucosides; Pyrazines; Small molecules; Thiophenes; Triazoles
- Mechanism of Action CD26 antigen inhibitors; Sodium-glucose transporter 2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Type 2 diabetes mellitus